0.31484.24% ( +0.0128 )
Trading: Nov 3, 11:44:31 (EDT)Current ValuationThe current P/E ratio is -0.20, above the reasonable range, cheaper than 0% of the time in the past 1 years, and the industry ranks 37/74, the industry Median --.
-0.203xP/E
$0.30Stock price
$-1.49Earnings per share
-0.203xP/E
Stock price$0.30Earnings per share$-1.49
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -1.78x
- Typical range
- -3.52x–-0.80x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
08162432
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
| Name/Symbol | |||
|---|---|---|---|
GHUSGuardant Health | -50.53x | 3.12% | $22.91B |
HIMSUSHims & Hers Health | -41.46x | 209.86% | $5.89B |
RDNTUSRadnet | -272.44x | 128.00% | $5.75B |
NEOUSNeogenomics | -65.60x | 71.60% | $2.12B |
WGSUSGeneDx | -17.97x | 359.59% | $1.91B |
AGLUSagilon health | -6.26x | 92.48% | $1.45B |
OPKUSOpko Health | -17.61x | 25.99% | $1.28B |
INNVUSInnovage | -479.76x | 2,301.70% | $1.22B |
LMRIUSLumexa Imaging | -38.63x | 145.51% | $1.07B |
CSTLUSCastle Biosciences | -54.98x | 50.00% | $1.07B |
AONCUSAmerican Oncology Network | -- | -- | $745.50M |
GMRSUSGMR Solutions | -7.93x | 91.45% | $600.18M |
FLGTUSFulgent Genetics | -6.29x | 42.64% | $530.77M |
PREUSPrenetics Global | -6.01x | 17.18% | $282.35M |
BDSXUSBiodesix | -8.28x | 42.80% | $229.80M |
CORBFUSGlobal Cord Blood Corporation | -- | -- | $127.35M |
AIRSUSAirSculpt Tech | -10.26x | 33.33% | $120.40M |
NAKAUSNakamoto | -0.24x | 102.50% | $99.14M |
PARKUSPark Dental Partners | -27.78x | -- | $98.20M |
GAMGUSGlobal Asset Management Group, Inc. | -171.89x | -- | $97.02M |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
